trending Market Intelligence /marketintelligence/en/news-insights/trending/RPv28xsr15-2Wp8LEnGudA2 content esgSubNav
In This List

TG Therapeutics begins US rolling submission of blood cancer therapy

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection

Video

S&P Capital IQ Pro | Powered by Advanced Visualization

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge


TG Therapeutics begins US rolling submission of blood cancer therapy

TG Therapeutics Inc. began its rolling submission with the U.S. Food and Drug Administration to market its medicine umbralisib as a treatment for two types of blood cancers.

The New York-based biopharmaceutical company is looking to market umbralisib as a treatment for marginal zone lymphoma and follicular lymphoma in patients who did not get better after receiving prior treatment. The drug has the FDA's orphan-drug and breakthrough-therapy designations in the marginal zone lymphoma indication.

The company said it began a single rolling submission, which is expected to be completed in the first half of the year.

TG Therapeutics' executive chairman and CEO, Michael Weiss, said the company is also working to advance other medicines, including a drug called ublituximab to treat multiple sclerosis. The company is also studying umbralisib as a treatment for newer indications.